However, 17252-m/z ApoAII heterodimer with -AT/−ATQ C-terminal ends (ApoAII-2) and 8766-m/z unglycosylated ApoCIII (ApoCIII-0) protein were found to be decreased most significantly in patients with pancreatic cancer, including those with early-stage (stages I and II) disease. The gene discussed is APOA2; the disease is pancreatic neoplasm.